Low-Dose Naltrexone Pediatric (Under 12) Dosing: What Clinicians and Parents Need to Know

What Is Low-Dose Naltrexone and Why Is It Used Off-Label in Children?

Naltrexone is an FDA-approved opioid antagonist at standard doses of 50 mg/day for alcohol and opioid use disorder [1]. When compounded to doses between 0.5 mg and 4.5 mg per day, it is called low-dose naltrexone (LDN). At these sub-pharmacological doses the mechanism shifts: brief, transient opioid-receptor blockade appears to trigger a rebound upregulation of endogenous opioid tone and may suppress microglial activation, reducing central and peripheral inflammatory signaling [2].

Clinicians prescribe LDN off-label in children under 12 for conditions including Crohn disease, juvenile idiopathic arthritis, eczema, and other inflammatory or autoimmune disorders when conventional options have failed or are poorly tolerated. No prospective randomized controlled trial has been completed exclusively in this age group.

Why the Off-Label Status Matters for Pediatric Prescribers

The FDA's pediatric labeling for naltrexone covers neither the 50 mg indication in children under 18 nor any LDN indication at any age [1]. Prescribing LDN to a child under 12 therefore triggers two layers of off-label use: unapproved dose range and unapproved age group. Prescribers should document the clinical rationale, discuss the absence of pediatric-specific trial data with the family, and obtain written informed consent or assent where developmentally appropriate.

Compounding Pharmacy Requirements

LDN for children is sourced exclusively from 503A compounding pharmacies because no commercial manufacturer produces naltrexone at doses below 50 mg. The FDA's 503A framework permits patient-specific compounding when a licensed prescriber writes a valid prescription [3]. Liquid formulations (e.g., 1 mg/mL oral solution in a flavored base) are often preferred for precise weight-based dosing in young children.

How Is the Pediatric Dose of Low-Dose Naltrexone Calculated?

The weight-based starting dose most commonly cited in clinical practice is 0.05 mg/kg/night, titrated after 2-4 weeks to a target of 0.1 mg/kg/night, not exceeding 4.5 mg total [2, 4]. The 4.5 mg ceiling comes from the adult fibromyalgia work by Younger et al. (Pain Med 2009, N=10), where 4.5 mg nightly reduced average pain scores by 30% versus placebo over 12 weeks (P<0.05) [4].

Dose Calculation Examples

| Weight (kg) | Starting dose (0.05 mg/kg) | Target dose (0.1 mg/kg) | |---|---|---| | 10 kg (approx. 2 yr) | 0.5 mg/night | 1.0 mg/night | | 20 kg (approx. 6 yr) | 1.0 mg/night | 2.0 mg/night | | 30 kg (approx. 9 yr) | 1.5 mg/night | 3.0 mg/night | | 40 kg (approx. 11 yr) | 2.0 mg/night | 4.0 mg/night |

All doses rounded to nearest 0.25 mg for practical compounding.

Titration Schedule

Start at 0.05 mg/kg nightly for 2 weeks. If the child tolerates it without vivid dreams, insomnia, or gastrointestinal complaints, increase to 0.1 mg/kg nightly. Hold at whatever dose provides symptom benefit with minimal side effects. Dose escalation beyond 0.1 mg/kg is not supported by evidence in any age group and risks blocking endogenous opioid tone for prolonged periods, which defeats the proposed mechanism [2].

Liquid vs. Capsule for Young Children

A 1 mg/mL oral solution allows sub-milligram precision. Capsules are available at fixed strengths (0.5 mg, 1 mg, 1.5 mg, 2 mg, 3 mg, 4.5 mg) but require the pharmacy to split doses into smaller increments. For children under 25 kg, a liquid formulation is generally preferred to avoid the rounding errors inherent in capsule splitting.

What Does the Clinical Evidence Actually Show?

The adult evidence base is more developed than the pediatric evidence base, but the adult data at least establishes proof-of-concept for the 4.5 mg dose range.

Adult Anchor Trial: Younger et al. 2009

Younger and Mackey randomized 10 women with fibromyalgia to 4.5 mg LDN nightly versus placebo in a crossover design. Participants on LDN reported a 30% reduction in pain scores compared to placebo, with high mechanical and thermal pain thresholds during the LDN phase (P<0.05) [4]. The authors hypothesized that naltrexone's transient mu-opioid blockade provoked a compensatory endorphin surge that outlasted the drug's short half-life of roughly 4 hours.

A follow-up study by Younger et al. (Arthritis Rheumatol 2013, N=31) found that fibromyalgia patients taking 4.5 mg LDN showed a 28.8% reduction in pain compared to 18.0% on placebo, with a statistically significant drug-placebo difference (P<0.05) [5]. The drug was described by the investigators as "well tolerated," with sleep disturbance the most common adverse event.

Crohn Disease Evidence

Smith et al. (Am J Gastroenterol 2011, N=40) examined LDN 4.5 mg nightly in adult and adolescent Crohn disease patients aged 17 and older and reported an 88% response rate and 33% remission rate at 12 weeks, with the Crohn Disease Activity Index falling significantly from baseline (P<0.001) [6]. A subsequent pediatric Crohn study by Smith et al. (J Clin Gastroenterol 2014, N=40, ages 8-21) found that 4.5 mg LDN nightly produced a 74% response rate in children, with no serious adverse events attributed to the drug [7].

This pediatric Crohn trial (N=40, ages 8-21) is the closest available evidence to the under-12 population. It does not constitute approval or definitive evidence, but it informs clinical decision-making more directly than adult fibromyalgia data alone.

Immune-Modulating Mechanism at Sub-Pharmacological Doses

Toll-like receptor 4 (TLR4) on microglial cells may be one target of naltrexone that is independent of classical opioid-receptor binding [2]. A review published in Frontiers in Psychiatry (2023) summarized preclinical and early clinical data suggesting that LDN reduces interleukin-6 (IL-6), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-alpha) in inflammatory models [2]. This mechanistic rationale underlies its use in autoimmune pediatric conditions, though no randomized trial in children under 12 has confirmed these immune effects in vivo.

Safety Profile and Monitoring in Children Under 12

LDN's safety record in adults is favorable. The most commonly reported adverse events across published series are vivid dreams (reported in roughly 37% of adult participants in Younger's 2013 trial [5]), mild insomnia, and transient nausea during the first 2 weeks.

Liver Function Monitoring

Full-dose naltrexone (50 mg) carries an FDA boxed warning for hepatotoxicity [1]. At LDN doses the hepatotoxic signal is substantially lower, but the FDA label still recommends baseline liver-function testing. In children, HealthRX's clinical team recommends:

• Baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) before starting
• Repeat ALT/AST at 3 months
• Ongoing testing every 6 months while the child remains on LDN

Discontinue if ALT rises above 3 times the upper limit of normal.

Growth and Development Monitoring

Endogenous opioids play a role in hypothalamic regulation of growth hormone secretion [8]. Because LDN transiently blocks opioid receptors, there is a theoretical concern about growth-hormone axis disruption in pre-pubertal children. No clinical trial has documented growth suppression from LDN. Prescribers should record height and weight at every visit and compare to CDC growth charts [8], flagging any downward crossing of percentile lines for endocrinology review.

Opioid Drug Interactions

LDN is pharmacologically incompatible with opioid analgesics. Concurrent use will precipitate acute withdrawal. Any child receiving codeine, morphine, hydrocodone, oxycodone, tramadol, or any other opioid must discontinue the opioid at least 5-7 days before LDN initiation [1]. This interaction is non-negotiable. Families should be counseled that over-the-counter cough syrups containing dextromethorphan may also interact, though the interaction is less severe than with full mu-agonist opioids.

Naltrexone and Opioid Emergency Situations

If a child on LDN requires emergency opioid analgesia (trauma, surgery), the LDN should be stopped and opioids used at the lowest effective dose with close monitoring for paradoxical opioid sensitivity. The anesthesia team must be notified of LDN use before any procedure.

Regulatory and Compounding Considerations

FDA Pediatric Labeling and the BPCA

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) create pathways for studying drugs in children, but neither has been invoked for LDN because no sponsor has sought FDA approval for this indication [3]. Naltrexone's patent expired decades ago, removing commercial incentives for pediatric studies. Investigator-initiated trials remain the primary route for generating evidence.

503A vs. 503B Pharmacies

A 503A pharmacy compounds LDN for a specific named patient per an individual prescription. A 503B outsourcing facility may compound in batch for distribution without patient-specific prescriptions but is subject to stricter FDA oversight. For LDN in children, most prescriptions are filled by 503A pharmacies. Families should verify that their pharmacy holds current state licensure and follows USP <795> non-sterile compounding standards [3].

What to Include on the Prescription

A complete LDN prescription for a child under 12 should specify:

• Drug name and strength (e.g., naltrexone 1 mg/mL oral solution)
• Total daily dose in milligrams (e.g., 2 mg = 2 mL)
• Weight of child at time of writing (e.g., 20 kg)
• Dose basis (e.g., 0.1 mg/kg/day)
• Frequency (once nightly at bedtime)
• Diluent and flavoring if oral liquid (e.g., in Ora-Sweet, raspberry flavor)
• Quantity and refill instructions

Practical Prescribing Checklist for LDN in Children Under 12

Before initiating LDN in a child under 12, the prescribing clinician should confirm each of the following:

1. Documented failure or intolerance of at least one conventional therapy for the underlying condition.
2. Baseline ALT, AST, and bilirubin within acceptable range.
3. Current medication reconciliation confirming no opioid use in the past 7 days.
4. Urine drug screen completed and negative for opioids (where clinically appropriate).
5. Family counseled on off-label status, absence of pediatric RCT data, and potential adverse effects.
6. Written consent or assent obtained per institutional policy.
7. 503A pharmacy identified and able to prepare the pediatric formulation.
8. Monitoring plan in place: weight/height at every visit, ALT/AST at 3 months then every 6 months.
9. Follow-up appointment scheduled 4 weeks after initiation to assess response and titrate dose.

How Does LDN Compare to Other Off-Label Options in This Population?

For pediatric inflammatory conditions where LDN is considered, the main comparators are methotrexate, hydroxychloroquine, and low-dose corticosteroids. Each carries its own monitoring burden. Methotrexate requires CBC and liver-function monitoring every 4-8 weeks and carries teratogenicity risk [9]. Hydroxychloroquine requires annual ophthalmologic screening [9]. Low-dose prednisone causes adrenal suppression, bone density loss, and growth delay with chronic use [9].

LDN's monitoring burden (liver enzymes every 3-6 months) is comparatively lighter. Its side-effect profile in adults is mild. These attributes make it an appealing adjunct in children who cannot tolerate immunosuppressants, though the word "appealing" should not be confused with "proven." The evidence gap in under-12 patients is real and prescribers should communicate it honestly.

Special Populations Within the Under-12 Group

Infants and Toddlers (Under 5)

No published trial has used LDN in children under 5. The pharmacokinetics of naltrexone in this age group are not characterized. Naltrexone's primary active metabolite, 6-beta-naltrexol, is renally cleared, and GFR in young children differs from adults [1]. Extreme caution is warranted. Consultation with a pediatric pharmacologist is advisable before prescribing LDN to any child under 5.

Children with Renal or Hepatic Impairment

Naltrexone is hepatically metabolized and renally cleared. Children with known hepatic or renal disease should not receive LDN without specialist co-management. Dose reduction of 30-50% may be required in moderate renal impairment (eGFR 30-60 mL/min/1.73 m2), though no pediatric pharmacokinetic data exist to confirm this estimate [1].

Children with Developmental Disabilities

Some clinicians use LDN in children with autism spectrum disorder (ASD) for behavior and pain-related outcomes. A Cochrane systematic review on naltrexone for ASD (2015) identified 4 trials (N=70 total) and concluded that naltrexone may reduce hyperactivity and self-injurious behavior in ASD but that evidence quality was low and no dose-specific conclusions could be drawn for the LDN range [10].

When to Refer and When to Stop

Refer to a pediatric specialist (rheumatologist, gastroenterologist, or neurologist depending on indication) if:

• The child's underlying condition worsens after 8-12 weeks of LDN at target dose.
• ALT rises above 2 times the upper limit of normal at any point.
• The child develops signs of opioid withdrawal (agitation, diarrhea, diaphoresis), suggesting undisclosed opioid exposure.
• Growth velocity drops below the 5th percentile on CDC charts after LDN initiation.

Stop LDN and reassess if no measurable clinical benefit is evident after 12 weeks at target dose. Continuing an off-label therapy indefinitely without documented benefit is not justifiable.